Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone

European Respiratory Journal

Volumn 42, Issue 2, 2013, Pages 394-403

  Farney, Robert J ^a   McDonald, Amanda M ^a   Boyle, Kathleen M ^a   Snow, Gregory L ^a   Nuttall, R T ^a   Coudreaut, Michael F ^a   Wander, Theodore J ^a   Walker, James M ^a  

^a LDS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE;

ADULT; AGED; APNEA HYPOPNEA INDEX; ARTICLE; BODY MASS; CONSULTATION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OXYGEN SATURATION; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PULSE OXIMETRY; SLEEP DISORDERED BREATHING; SLEEP MEDICINE; SLEEP TIME;

ADOLESCENT; ADULT; BUPRENORPHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; POLYSOMNOGRAPHY; RESPIRATION; SLEEP APNEA SYNDROMES; YOUNG ADULT;

EID: 84882726713     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00120012     Document Type: Article

References (45)

1. Farney RJ, Walker JM, Cloward TV, et al. Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003; 123: 632-639.
2. Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007; 3: 455-461.
3. Teichtahl H, Prodomidis A, Miller B, et al. Sleep-disordered breathing in stable methadone programme patients: a pilot study. Addiction 2001; 96: 395-403.
4. Webster LR, Choi Y, Desai H, et al. Sleep-disordered breathing and chronic opioid therapy. PainMed 2008; 9: 425-432.
5. Farney RJ, Walker JM. Central sleep apnea due to drug or substance. In: Kushida C, ed. The Encyclopedia of Sleep. Vol. 3. Waltham, MA, Academic Press, 2013; pp. 253-264.
6. Centers for Disease Control and Prevention (CDC). Increase in poisoning deaths caused by non-illicit drugs - Utah, 1991-2003. MMWR Morb Mortal Wkly Rep 2005; 54: 33-36.
7. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011; 60: 1487-1492.
8. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008; 108: 812-821.
9. Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007; 297: 249-251.
10. Office of Diversion Control. National Forensic Laboratory Information System (NFLIS). Special Report: Methadone and Buprenorphine, 2003-2008. Washington, US Drug Enforcement Administration, 2009.
11. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569-580.
12. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005; 29: 297-326.
13. Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011; 57: 281-289.
14. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96: 627-632.
15. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94: 825-834.
16. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285: 45.
17. Auriacombe M, Fatséas M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict 2004; 13: Suppl. 1, S17-S28.
18. Substance Abuse and Mental Health Services Administration. Buprenorphine Drug Addiction Treatment Act of 2000. http://buprenorphine.samhsa.gov/fulllaw. html Date last accessed: June 9, 2013. Date last updated: 2000.
19. Ladi L, Wang J, Getsy J. Sleep-disordered breathing with buprenorphine-naloxone use: a case report. Chest 2010; 138: 700A.
20. McNicholas L. Clinical Guidelines for the use of Buprenorphine in the Treatment of Opioid Addiction. A Treatment Improvement Protocol. TIP 40. Rockville, US Department of Health and Human Services, 2004.
21. Farney RJ, Walker JM, Cloward TV, et al. Polysomnography in hospitalized patients using a wireless wide area network. J Clin Sleep Med 2006; 2: 28-34.
22. Iber C, Ancoli-Israel S, Chesson A, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. 1st Edn. Westchester, American Academy of Sleep Medicine, 2007.
23. Farney RJ, Walker JM, Boyle KM, et al. Adaptive servoventilation (ASV) in patients with sleep disordered breathing associated with chronic opioid medications for non-malignant pain. J Clin Sleep Med 2008; 4: 311-319.
24. Breiman L. Random forests. Machine Learning 2001; 45: 5-32.
25. Breiman L. Manual on Setting Up, Using, and Understanding Random Forests V3.1. http://oz.berkeley.edu/users/ breiman/Using-random-forests-V31.pdf Date last accessed: June 10, 2013.
26. Liaw A, Wiener M. Classification and regression by random forest. R News 2002; 2: 18-22.
27. Conover WJ. One-sample Kolmogorov test. Practical Nonparametric Statistics. 1st Edn. New York, John Wiley & Sons, 1971; pp. 295-301.
28. Conover WJ. Two-sample Smirnov test. Practical Nonparametric Statistics. 1st Edn. New York, John Wiley & Sons, 1971; pp. 309-314.
29. Farney RJ, Walker BS, Farney RM, et al. The STOP-Bang equivalent model and prediction of severity of obstructive sleep apnea: relation to polysomnographic measurements of the apnea/hypopnea index. J Clin Sleep Med 2011; 7: 459-465.
30. Hukins C. Mallampati class is not useful in the clinical assessment of sleep clinic patients. J Clin Sleep Med 2010; 6: 545-549.
31. Bowman AWA. Applied Smoothing Techniques for Data Analysis. The Kernel Approach with S-Plus Illustrations. NewYork, Oxford University Press, 1997.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
33. Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev 2006; 25: 79-85.
34. Labby D., Koder M., Amann T. Opioids and Chronic Non-Malignant Pain: A Clinician?s Handbook. Portland, CareOregon, 2003.
35. Pattinson KT. Opioids and the control of respiration. Br J Anaesth 2008; 100: 747-758.
36. Pasternak GW. Incomplete cross tolerance and multiple m-opioid peptide receptors. Trends Pharmacol Sci 2001; 22: 67-70.
37. Xie GX, Palmer PP. RGS proteins: new players in the field of opioid signaling and tolerance mechanisms. Anesth Analg 2005; 100: 1034-1042.
38. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70: Suppl. 2, S13-S27.
39. Walsh SL, Preston KL, Bigelow GE, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274: 361-372.
40. Walsh SL, June HL, Schuh KJ, et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995; 119: 268-276.
41. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65-69.
42. Kintz P. A new series of buprenorphine-related deaths. Clin Biochem 2002; 35: 513-516.
43. Boyd J, Randell T, Luurila H, et al. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003; 47: 1031-1033.
44. Mogri M, Desai H, Webster L, et al. Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath 2009; 13: 49-57.
45. Javaheri S, Malik A, Smith J, et al. Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids. J Clin Sleep Med 2008; 4: 305-310.